Letermovir use to treat complex cytomegalovirus reactivations in two heart transplant recipients

Letermovir, an anti-cytomegalovirus (CMV) drug, is recommended as a prophylactic agent in patients at risk of CMV infection/reactivation after allogeneic hematopoietic stem cell transplant. We report the curative and pre-emptive use of letermovir in two heart transplant recipients. In one patient wi...

Full description

Saved in:
Bibliographic Details
Published in:Antiviral therapy 2022-12, Vol.27 (6), p.135965352211336-13596535221133619
Main Authors: Boignard, Aude, Augier, Caroline, Kheng, Mathilde, Epaulard, Olivier, Germi, Raphaele
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Letermovir, an anti-cytomegalovirus (CMV) drug, is recommended as a prophylactic agent in patients at risk of CMV infection/reactivation after allogeneic hematopoietic stem cell transplant. We report the curative and pre-emptive use of letermovir in two heart transplant recipients. In one patient with ganciclovir-resistant CMV, letermovir was successfully used to treat CMV colitis. In the second patient, letermovir was used as pre-emptive therapy for CMV reactivation, but did not prevent CMV esophagitis. In both cases, letermovir was successful for secondary prophylaxis. Curative use of letermovir may be considered if resistance or major adverse effect of other antivirals therapy is suspected.
ISSN:1359-6535
2040-2058
DOI:10.1177/13596535221133619